Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
22
CLRB Quote, Financials, Valuation and Earnings
Last price:
$2.73
Seasonality move
:
3.11%
Day range:
$2.80 - $2.91
52-week range:
$2.45 - $20.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
0.66x
Volume:
47.7K
Avg. volume:
67.4K
1-year change:
-59.43%
Market cap:
$4.9M
Revenue:
--
EPS (TTM):
-$6.47
Analysts' Opinion
-
Consensus RatingCellectar Biosciences, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.00, Cellectar Biosciences, Inc. has an estimated upside of 1543.36% from its current price of $2.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $2.86.
Fair Value
-
According to the consensus of 4 analysts, Cellectar Biosciences, Inc. has 1543.36% upside to fair value with a price target of $47.00 per share.
CLRB vs. S&P 500
-
Over the past 5 trading days, Cellectar Biosciences, Inc. has underperformed the S&P 500 by -12.37% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cellectar Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellectar Biosciences, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Cellectar Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Cellectar Biosciences, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cellectar Biosciences, Inc. reported earnings per share of -$1.41.
Enterprise value:
-5M
EV / Invested capital:
-0.51x
Price / LTM sales:
137.94x
EV / EBIT:
--
EV / Revenue:
-0.16x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$232.7K
Return On Assets:
-87.98%
Net Income Margin (TTM):
--
Return On Equity:
-160.56%
Return On Invested Capital:
-154.34%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$160.6K | -$293K | -$232.7K | -$68.6K | -$52.3K | |
| Operating Income | -$33.8M | -$51.6M | -$30M | -$13.3M | -$4.9M | |
| EBITDA | -$33.7M | -$51.3M | -$29.8M | -$13.3M | -$4.8M | |
| Diluted EPS | -$132.75 | -$1.87 | -$6.47 | -$0.37 | -$1.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $41.4M | $18.8M | $20.1M | $35.9M | $13.6M | |
| Total Assets | $42M | $19.3M | $21.6M | $37.3M | $14.6M | |
| Current Liabilities | $3.2M | $6.5M | $16.5M | $20.3M | $4.9M | |
| Total Liabilities | $3.4M | $6.6M | $17M | $20.7M | $5.2M | |
| Total Equity | $38.6M | $12.8M | $4.6M | $16.5M | $9.4M | |
| Total Debt | $202K | $53.8K | $512.8K | $431.9K | $335.9K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.2M | -$46.3M | -$29.7M | -$9.2M | -$4.3M | |
| Cash From Investing | -$715.1K | -$309.7K | -$61.3K | -- | -- | |
| Cash From Financing | $32.1M | $61.9M | $8M | $17.6M | $5.8M | |
| Free Cash Flow | -$30.9M | -$46.6M | -$29.7M | -$9.2M | -$4.3M | |
CLRB
Sector
Market Cap
$4.9M
$28.1M
Price % of 52-Week High
13.26%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-79.04%
-1.49%
1-Year Price Total Return
-59.43%
-17.13%
Beta (5-Year)
0.471
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.10
200-day SMA
Sell
Level
$6.23
Bollinger Bands (100)
Sell
Level
3.38 - 5.18
Chaikin Money Flow
Sell
Level
-18.4M
20-day SMA
Sell
Level
$3.42
Relative Strength Index (RSI14)
Sell
Level
37.37
ADX Line
Sell
Level
25.55
Williams %R
Neutral
Level
-74.375
50-day SMA
Sell
Level
$3.54
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
12.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.6405)
Sell
CA Score
(Annual)
Level (-14.9616)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (14.5223)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.
Stock Forecast FAQ
In the current month, CLRB has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CLRB average analyst price target in the past 3 months is $47.00.
-
Where Will Cellectar Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellectar Biosciences, Inc. share price will rise to $47.00 per share over the next 12 months.
-
What Do Analysts Say About Cellectar Biosciences, Inc.?
Analysts are divided on their view about Cellectar Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellectar Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Cellectar Biosciences, Inc.'s Price Target?
The price target for Cellectar Biosciences, Inc. over the next 1-year time period is forecast to be $47.00 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CLRB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellectar Biosciences, Inc. is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CLRB?
You can purchase shares of Cellectar Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellectar Biosciences, Inc. shares.
-
What Is The Cellectar Biosciences, Inc. Share Price Today?
Cellectar Biosciences, Inc. was last trading at $2.73 per share. This represents the most recent stock quote for Cellectar Biosciences, Inc.. Yesterday, Cellectar Biosciences, Inc. closed at $2.86 per share.
-
How To Buy Cellectar Biosciences, Inc. Stock Online?
In order to purchase Cellectar Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CLRB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLRB
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
0.66x
1.81x
Price / LTM sales
137.94x
1.59x
Growth Metrics
CLRB
Sector
Revenue growth
--
4.62%
Earnings growth
-276.99%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$2.53
-$0.21
Profitability
CLRB
Sector
Profitability FY 2024
-$291.7K
$3.6M
Return on invested capital
-154.34%
-31.84%
Return on assets
-87.98%
-27.96%
Return on equity
-160.56%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
12
Balance Sheet
CLRB
Sector
Total cash
$12.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$25.5M
$76.9M
Long term debt
$335.9K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.24% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
